Nafros (Sodium Fluoride (18f))

Sodium Fluoride‑18 exchanges its fluoride ion with hydroxyl groups in bone hydroxyapatite, becoming incorporated into the bone matrix. The radioactive fluorine emits positrons that are captured by PET scanners, producing detailed images of bone metabolic activity.

The administered activity of Nafros is determined by the prescribing physician based on the patient’s weight, the imaging protocol, and regulatory guidelines. The exact dose is individualized and should be ordered by a qualified nuclear medicine specialist.

Safety data for Nafros in pregnancy and lactation are limited. It is generally avoided unless the diagnostic benefit outweighs potential risks to the fetus or infant. Clinicians should discuss alternatives and obtain informed consent when considering use in these populations.

To order Nafros, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and import documentation.

Compared with traditional bone scintigraphy agents such as Technetium‑99m‑MDP, Nafros (Sodium Fluoride‑18) offers higher spatial resolution, faster blood clearance, and more precise quantification of bone turnover, making it preferable for detailed PET imaging of skeletal lesions.

Nafros must be stored refrigerated at 2‑8 °C, protected from light, and should never be frozen or shaken. Use aseptic technique during preparation and administer promptly after removal from storage to maintain radiochemical integrity.

Nafros is given as an intravenous injection by a qualified healthcare professional. The dose is administered slowly, followed by a waiting period (typically 30‑60 minutes) before PET imaging to allow adequate bone uptake of the tracer.

The most serious risks include severe allergic reactions (anaphylaxis), marked hypotension, and radiation‑related tissue injury at high cumulative doses. Immediate medical attention is required if any signs of anaphylaxis or hemodynamic instability occur.

Nafros should not be used in patients with known hypersensitivity to sodium fluoride or any component of the formulation, in those who have received other bone‑seeking radiopharmaceuticals within a short interval, or in pregnant women unless the diagnostic benefit justifies the potential risk.